Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC

Clinical trial NCT05608213 · RECRUITING

Trial details

NCT number: NCT05608213
Sponsor: Second Affiliated Hospital of Guangzhou Medical University
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Hepatocellular Carcinoma Non-resectable

Start date: 2022-11-02
Primary completion: 2026-10-31
Enrollment: 187

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.